115 related articles for article (PubMed ID: 29221170)
1. Proteoglycan-targeting applied to hypoxia-activated prodrug therapy in chondrosarcoma: first proof-of-concept.
Voissiere A; Weber V; Gerard Y; Rédini F; Raes F; Chezal JM; Degoul F; Peyrode C; Miot-Noirault E
Oncotarget; 2017 Nov; 8(56):95824-95840. PubMed ID: 29221170
[TBL] [Abstract][Full Text] [Related]
2. Structure-activity relationship study of hypoxia-activated prodrugs for proteoglycan-targeted chemotherapy in chondrosarcoma.
Ghedira D; Voissière A; Peyrode C; Kraiem J; Gerard Y; Maubert E; Vivier M; Miot-Noirault E; Chezal JM; Farhat F; Weber V
Eur J Med Chem; 2018 Oct; 158():51-67. PubMed ID: 30199705
[TBL] [Abstract][Full Text] [Related]
3. Design, synthesis and evaluation of targeted hypoxia-activated prodrugs applied to chondrosarcoma chemotherapy.
Gerard Y; Voissière A; Peyrode C; Galmier MJ; Maubert E; Ghedira D; Tarrit S; Gaumet V; Canitrot D; Miot-Noirault E; Chezal JM; Weber V
Bioorg Chem; 2020 May; 98():103747. PubMed ID: 32208207
[TBL] [Abstract][Full Text] [Related]
4. Doxycycline and its quaternary ammonium derivative for adjuvant therapies of chondrosarcoma.
Miladi I; Vivier M; Dauplat MM; Chatard M; Besse S; Vidal A; Chassain K; Jean B; Forestier C; Chezal JM; Rédini F; Degoul F; Miot-Noirault E
Cancer Chemother Pharmacol; 2017 Sep; 80(3):517-526. PubMed ID: 28707014
[TBL] [Abstract][Full Text] [Related]
5. Proteoglycans as Target for an Innovative Therapeutic Approach in Chondrosarcoma: Preclinical Proof of Concept.
Peyrode C; Weber V; Voissière A; Maisonial-Besset A; Vidal A; Auzeloux P; Gaumet V; Borel M; Dauplat MM; Quintana M; Degoul F; Rédini F; Chezal JM; Miot-Noirault E
Mol Cancer Ther; 2016 Nov; 15(11):2575-2585. PubMed ID: 27573424
[TBL] [Abstract][Full Text] [Related]
6. Development and characterization of a human three-dimensional chondrosarcoma culture for in vitro drug testing.
Voissiere A; Jouberton E; Maubert E; Degoul F; Peyrode C; Chezal JM; Miot-Noirault É
PLoS One; 2017; 12(7):e0181340. PubMed ID: 28704566
[TBL] [Abstract][Full Text] [Related]
7. Quaternary ammonium-melphalan conjugate for anticancer therapy of chondrosarcoma: in vitro and in vivo preclinical studies.
Peyrode C; Weber V; David E; Vidal A; Auzeloux P; Communal Y; Dauplat MM; Besse S; Gouin F; Heymann D; Chezal JM; Rédini F; Miot-Noirault E
Invest New Drugs; 2012 Aug; 30(4):1782-90. PubMed ID: 21499733
[TBL] [Abstract][Full Text] [Related]
8. Small rigid platforms functionalization with quaternary ammonium: targeting extracellular matrix of chondrosarcoma.
Miot-Noirault E; Vidal A; Morlieras J; Bonazza P; Auzeloux P; Besse S; Dauplat MM; Peyrode C; Degoul F; Billotey C; Lux F; Rédini F; Tillement O; Chezal JM; Kryza D; Janier M
Nanomedicine; 2014 Nov; 10(8):1887-95. PubMed ID: 24972007
[TBL] [Abstract][Full Text] [Related]
9. Relevance of the combination of external beam radiotherapy with the hypoxia-activated prodrug ICF05016 in an experimental model of extraskeletal myxoid chondrosarcoma.
Maubert E; Weber V; Voissière A; Gérard Y; Dedieu V; Degoul F; Chezal JM; Chautard E; Miot-Noirault E
Invest New Drugs; 2021 Apr; 39(2):295-303. PubMed ID: 32948981
[TBL] [Abstract][Full Text] [Related]
10. Proof of Concept of the Radiosensitizing Effect of Gadolinium Oxide Nanoparticles in Cell Spheroids and a Tumor-Implanted Murine Model of Chondrosarcoma.
Aloy MT; Sidi Boumedine J; Deville A; Kryza D; Gauthier A; Brichart-Vernos D; Ollier G; La Padula V; Lux F; Tillement O; Rodriguez-Lafrasse C; Janier M
Int J Nanomedicine; 2022; 17():6655-6673. PubMed ID: 36582458
[TBL] [Abstract][Full Text] [Related]
11. Simultaneous proteoglycans and hypoxia mapping of chondrosarcoma environment by frequency selective CEST MRI.
Autissier R; Mazuel L; Maubert E; Bonny JM; Auzeloux P; Schmitt S; Traoré A; Peyrode C; Miot-Noirault E; Pagés G
Magn Reson Med; 2021 Aug; 86(2):1008-1018. PubMed ID: 33772858
[TBL] [Abstract][Full Text] [Related]
12. Activity of the hypoxia-activated pro-drug TH-302 in hypoxic and perivascular regions of solid tumors and its potential to enhance therapeutic effects of chemotherapy.
Saggar JK; Tannock IF
Int J Cancer; 2014 Jun; 134(11):2726-34. PubMed ID: 24338277
[TBL] [Abstract][Full Text] [Related]
13. Preclinical development and current status of the fluorinated 2-nitroimidazole hypoxia probe N-(2-hydroxy-3,3,3-trifluoropropyl)-2-(2-nitro-1-imidazolyl) acetamide (SR 4554, CRC 94/17): a non-invasive diagnostic probe for the measurement of tumor hypoxia by magnetic resonance spectroscopy and imaging, and by positron emission tomography.
Aboagye EO; Kelson AB; Tracy M; Workman P
Anticancer Drug Des; 1998 Sep; 13(6):703-30. PubMed ID: 9755726
[TBL] [Abstract][Full Text] [Related]
14. Synthesis and pharmacokinetic profile of a quaternary ammonium derivative of chlorambucil, a potential anticancer drug for the chemotherapy of chondrosarcoma.
Rapp M; Giraud I; Maurizis JC; Madelmont JC
Bioorg Med Chem; 2003 Nov; 11(23):5007-12. PubMed ID: 14604663
[TBL] [Abstract][Full Text] [Related]
15. Hypoxia-Activated Prodrug TH-302 Targets Hypoxic Bone Marrow Niches in Preclinical Leukemia Models.
Benito J; Ramirez MS; Millward NZ; Velez J; Harutyunyan KG; Lu H; Shi YX; Matre P; Jacamo R; Ma H; Konoplev S; McQueen T; Volgin A; Protopopova M; Mu H; Lee J; Bhattacharya PK; Marszalek JR; Davis RE; Bankson JA; Cortes JE; Hart CP; Andreeff M; Konopleva M
Clin Cancer Res; 2016 Apr; 22(7):1687-98. PubMed ID: 26603259
[TBL] [Abstract][Full Text] [Related]
16. Differentiation of adipose-derived stem cells toward nucleus pulposus-like cells induced by hypoxia and a three-dimensional chitosan-alginate gel scaffold in vitro.
Zhang Z; Li F; Tian H; Guan K; Zhao G; Shan J; Ren D
Chin Med J (Engl); 2014; 127(2):314-21. PubMed ID: 24438622
[TBL] [Abstract][Full Text] [Related]
17. Selective tumor targeting by the hypoxia-activated prodrug AQ4N blocks tumor growth and metastasis in preclinical models of pancreatic cancer.
Lalani AS; Alters SE; Wong A; Albertella MR; Cleland JL; Henner WD
Clin Cancer Res; 2007 Apr; 13(7):2216-25. PubMed ID: 17404106
[TBL] [Abstract][Full Text] [Related]
18. Mechanism of action and preclinical antitumor activity of the novel hypoxia-activated DNA cross-linking agent PR-104.
Patterson AV; Ferry DM; Edmunds SJ; Gu Y; Singleton RS; Patel K; Pullen SM; Hicks KO; Syddall SP; Atwell GJ; Yang S; Denny WA; Wilson WR
Clin Cancer Res; 2007 Jul; 13(13):3922-32. PubMed ID: 17606726
[TBL] [Abstract][Full Text] [Related]
19. Hypoxia-activated prodrugs: substituent effects on the properties of nitro seco-1,2,9,9a-tetrahydrocyclopropa[c]benz[e]indol-4-one (nitroCBI) prodrugs of DNA minor groove alkylating agents.
Tercel M; Atwell GJ; Yang S; Stevenson RJ; Botting KJ; Boyd M; Smith E; Anderson RF; Denny WA; Wilson WR; Pruijn FB
J Med Chem; 2009 Nov; 52(22):7258-72. PubMed ID: 19877646
[TBL] [Abstract][Full Text] [Related]
20. The synthesis and radiolabeling of 2-nitroimidazole derivatives of cyclam and their preclinical evaluation as positive markers of tumor hypoxia.
Engelhardt EL; Schneider RF; Seeholzer SH; Stobbe CC; Chapman JD
J Nucl Med; 2002 Jun; 43(6):837-50. PubMed ID: 12050331
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
